Prevalence and Treatment Patterns of Opioid Use Disorder in Two Commercial Populations

December 21, 2017
Download Poster (350.31 KB)

This poster was presented at the 30th annual  Psych Congress, held Sept. 16-19, 2017, in New Orleans, Louisiana.

Background: Opioid use disorder (OUD) affects 2.5 million people in the United States (US), has a negative impact on population health, and has adverse social and economic consequences. Opioid overdose deaths have quadrupled since 1999. Our objective was to quantify the OUD epidemic and understand current treatment patterns among insured individuals.

Methods: Using the Truven MarketScan Commercial and Optum Clinformatics Commercial databases, subjects with ≥1 claim for OUD and continuous coverage for each calendar year between 2011 and 2015 were identified. The annual age-adjusted prevalence rate of OUD was calculated for each year by direct standardization of the OUD prevalence using the 2010 US Census. Rates of treatment with detoxification, psychosocial treatment, and medication-assisted treatment (MAT) were also assessed.

Results: In the Truven database, the age-adjusted prevalence of OUD increased from 0.26% in 2011 to 0.47% in 2015. From 2011 to 2015, individuals receiving detoxification decreased from 20.61% to 13.49%. The same trend was observed for psychosocial treatment (59.86% to 41.32%) and MAT (46.26% to 33.76%). Similar trends for prevalence and treatment were found in the Optum database. The age-adjusted OUD prevalence increased from 0.32% to 0.62% between 2011 and 2015. Rates of treatment decreased from 2011-2015 [detoxification (11.70% to 9.85%); psychosocial treatment (48.95% to 31.66%); MAT (35.31% to 24.12%)].

Conclusions: Increasing OUD prevalence rates have not been matched by increasing treatment rates. Understanding geographic variations and barriers to treatment could assist in planning cost-effective strategies to assist with combating the opioid epidemic.

Margaret Duncan, MD, PhD; Yuexi Wang, ME; Lin Xie, MS, MA; Onur Baser, PhD, MS; Mugdha Gore, PhD, BPharm
Sponsoring Organization: 
Alkermes, Inc.
Substance Abuse, Addiction & Deterrence